These results indicate that Nrf2 acts as a critical negative regulator of Dox-induced cardiomyopathy, thereby identifying a potential, novel target for the treatment of Dox-induced cardiomyopathy. This evidence concerns the gene NFE2L2 and cardiomyopathy.